Summary
TD5A Chart
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
TNDM's global expansion and strategic integrations fuel growth potential, even as pump reliance and macro pressures weigh on performance.
Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript
Tandem Diabetes Care, Inc. ( TNDM ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Leigh Vosseller - Executive VP, CFO & Treasurer Conference Call Participants Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Danielle Antalffy - UBS Investment Bank, Research Division Michael Kratky - Leerink Partners LLC, Research Division Joanne Wuensch - Citigroup Inc. Exchange Research Suraj Kalia - Oppenheimer & Co. Inc., Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Polark - Wolfe Research, LLC Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Stephanie Piazzola - BofA Securities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and thank you for standing by.
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care Inc. (TD5A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Tandem Diabetes Care Inc. ever had a stock split?
Tandem Diabetes Care Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | John F. Sheridan CEO | XSTU Exchange | US8753722037 ISIN |
| US Country | 2,650 Employees | - Last Dividend | 10 Oct 2017 Last Split | 14 Nov 2013 IPO Date |
Overview
Tandem Diabetes Care, Inc. is a leading medical device company dedicated to enhancing the lives of individuals with diabetes worldwide through innovative technology solutions. Originating as Phluid Inc., the company was rebranded to Tandem Diabetes Care, Inc. in January 2008, reflecting its focused mission on diabetes management solutions. Since its incorporation in 2006, Tandem Diabetes Care has been committed to development, design, and commercialization efforts centered around advancing diabetes care. Headquartered in San Diego, California, Tandem offers a wide array of products that significantly improve the management of diabetes for its users in the United States and across the globe.
Products and Services
- t:slim X2 Insulin Delivery System: The flagship product of Tandem, the t:slim X2, is an innovative insulin pump platform that enhances insulin management. It integrates continuous glucose monitoring (CGM) sensor information, displaying it directly on the home screen of the pump for convenience and ease-of-use. This integration facilitates real-time diabetes management by allowing for immediate adjustments.
- Tandem Mobi Insulin Pump: As an automated insulin delivery system, the Tandem Mobi pump represents the latest in Tandem's product innovations. Designed to provide a compact, flexible insulin delivery solution, it supports users in achieving optimal glycemic control with minimal manual intervention.
- Single-Use Products: Tandem also offers essential single-use products such as cartridges, which are integral for insulin storage and delivery, and infusion sets that securely connect the insulin pump to the user. These consumable components are designed for ease-of-use and reliability.
- Tandem Device Updater: Understanding the need for continuous improvement, the Tandem Device Updater enables users to update their pump’s software conveniently from a personal computer. This feature ensures that users have access to the latest functionalities and improvements without needing a new device.
- Tandem Source: A web-based data management platform, Tandem Source, provides users and healthcare providers with a comprehensive visual display of diabetes therapy management data. This platform integrates data from the pumps, CGMs, and supported blood glucose meters, facilitating a holistic view of the user's diabetes management.
- Sugarmate: This mobile application complements Tandem’s product ecosystem by helping users visualize their diabetes therapy data in an easily accessible format. Sugarmate enables users to track their glucose levels, insulin doses, and more, directly from their smartphones, fostering more informed diabetes management decisions.
Contact Information
